# Reading list

> Meno Peptides bibliography — The Meno Peptides bibliography: published bremelanotide and kisspeptin studies and reviews on desire, appetite, bone and reproductive signalling.

The most useful company for an interesting result is often another paper asking a less convenient question.

## Desire trials

The [RECONNECT trials](https://pubmed.ncbi.nlm.nih.gov/31599840/) and their [open-label extension](https://pubmed.ncbi.nlm.nih.gov/31599847/) supply the central clinical results discussed here. The [critical regulatory review](https://doi.org/10.1136/dtb.2021.000020) belongs beside them, in my opinion, followed by the [brain-imaging study](https://pubmed.ncbi.nlm.nih.gov/36189794/). The disagreement over enjoyable experience gives the desire scores a more demanding context.

The [pharmacotherapy review](https://doi.org/10.1007/s11920-022-01322-7) distinguishes premenopausal and postmenopausal care. The [2019 first-approval account](https://pubmed.ncbi.nlm.nih.gov/31312037/) and [prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) supply the historical indication and the cardiovascular cautions discussed in the desire chapter.

## Appetite and bone

The [kisspeptin food-intake experiment](https://pubmed.ncbi.nlm.nih.gov/37039248/) and the [bremelanotide metabolic experiments](https://pubmed.ncbi.nlm.nih.gov/35170192/) make an interesting pair, provided their separate designs remain visible. The [mouse receptor-knockout study](https://pubmed.ncbi.nlm.nih.gov/24937427/) supplies a different kind of metabolic question.

For bone, begin with the [acute marker study in healthy men](https://pubmed.ncbi.nlm.nih.gov/35244717/), then turn to the [mouse osteoclast experiment](https://pubmed.ncbi.nlm.nih.gov/38346942/). The move from healthy men to mice is the reason to read both closely.

## Discovery and changing responsiveness

The [melanoma discovery paper](https://pubmed.ncbi.nlm.nih.gov/8944003/) and [GPR54 genetics paper](https://pubmed.ncbi.nlm.nih.gov/14573733/) give kisspeptin its unexpected opening chapters. The [repeated-exposure experiment](https://pubmed.ncbi.nlm.nih.gov/19820030/), [LH-pulse experiment](https://pubmed.ncbi.nlm.nih.gov/24517142/) and [receptor pharmacology review](https://pubmed.ncbi.nlm.nih.gov/25765628/) address the changing hormone response.

The [anxiety crossover study](https://pubmed.ncbi.nlm.nih.gov/40036336/) and [systematic review of clinical status](https://pubmed.ncbi.nlm.nih.gov/38265397/) round out the discussion.

## References

[1] Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/31599840/
[2] Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder https://pubmed.ncbi.nlm.nih.gov/31599847/
[3] Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder https://pubmed.ncbi.nlm.nih.gov/36189794/
[4] Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. https://doi.org/10.1136/dtb.2021.000020
[5] Bremelanotide Injection — US Prescribing Information (DailyMed/FDA) https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[6] Pharmacotherapy for Sexual Dysfunction in Women. https://doi.org/10.1007/s11920-022-01322-7
[7] Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials https://pubmed.ncbi.nlm.nih.gov/35170192/
[8] The effects of kisspeptin on food intake in women with overweight or obesity https://pubmed.ncbi.nlm.nih.gov/37039248/
[9] Acute effects of kisspeptin administration on bone metabolism in healthy men https://pubmed.ncbi.nlm.nih.gov/35244717/
[10] Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src https://pubmed.ncbi.nlm.nih.gov/38346942/
[11] KiSS-1, a novel human malignant melanoma metastasis-suppressor gene https://pubmed.ncbi.nlm.nih.gov/8944003/
[12] The GPR54 gene as a regulator of puberty https://pubmed.ncbi.nlm.nih.gov/14573733/
[13] Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis https://pubmed.ncbi.nlm.nih.gov/19820030/
[14] Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54 https://pubmed.ncbi.nlm.nih.gov/24517142/
[15] Kisspeptin administration stimulates reproductive hormones but does not affect anxiety in humans https://pubmed.ncbi.nlm.nih.gov/40036336/
[16] KISS1R: Hallmarks of an Effective Regulator of the Neuroendocrine Axis https://pubmed.ncbi.nlm.nih.gov/25765628/
[17] Kisspeptin and its current clinical status - a systematic review https://pubmed.ncbi.nlm.nih.gov/38265397/
[18] Bremelanotide: First Approval https://pubmed.ncbi.nlm.nih.gov/31312037/
[19] Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity https://pubmed.ncbi.nlm.nih.gov/24937427/

---

At Meno Peptides I pursue the unfinished menopause chapter in published research, with curiosity to spare and no medical advice to offer.